Amgen is a leading biotechnology company that focuses on the development, manufacturing, and commercialization of innovative therapeutic solutions to treat serious illnesses
The company leverages its advanced science and research capabilities to create biologic therapies that target various medical conditions, including cancer, kidney disease, and rheumatoid arthritis. Through a commitment to scientific excellence, Amgen aims to enhance patient care by providing effective treatments that improve health outcomes and quality of life. Additionally, the company engages in extensive research collaborations and partnerships, further advancing its mission to deliver groundbreaking therapies to patients around the world.
Since September 2024, Amgen has been in a holding pattern, posting a small loss of 1.8% while floating around $314.91. The stock also fell short of the S&P 500’s 7% gain during that period.
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQAMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company.
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Many of the top-performing stocks and assets in recent years have stumbled at the start of 2025, with Bitcoin (CRYPTO: BTC) dropping to a three-month low.
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also exist.
Shares of biotech company Amgen (NASDAQAMGN)
jumped 5.3% in the afternoon session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this quarter, and its full-year revenue guidance came in slightly higher than Wall Street's estimates.
On the other hand, its full-year EPS guidance slightly missed, and its EPS was in line with Wall Street's estimates.
Overall, this quarter was mixed with better-than-anticipated sales but mediocre profitability. The market seemed to focus on the sales, and the stock traded up as a result.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
